The objective of this development program was to design an age-appropriate multi-dose liquid product suitable for the neonate population (up to 28 days old).
Request a copy of our scientific poster from EUPFI 2019 titled, 'Development of Oral Liquid Products for Neonatal Patients'.
Have a question about your pediatric drug program? Ask a member of our team about our capabilities for drug product clinical manufacturing, commercial manufacturing, or clinical testing to keep your pediatric drug program on-track.
Chief Scientific Officer
Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...
About AndrewExecutive Director, Pediatric Services
Nazim Kanji has over 25 years of experience in the pharmaceutical and consumer healthcare industries, where he has worked in produ...
About NazimVP, Integrated Development Services
Dr. Asma Patel is responsible for providing scientific and technical support to Quotient Sciences' business development group and ...
About Asma